Viz.ai, a global leader in AI-powered disease detection and intelligent care coordination, has announced a new partnership with the Addario Lung Cancer Medical Institute (ALCMI), a global consortium of 25 premier lung cancer research institutions. The objective of the collaboration is to enhance lung cancer outcomes by utilizing AI for precision medicine and early detection. Their mutual objective is to optimize treatment plans by utilizing AI-powered tools and to expedite clinical workflows, particularly in the nodule workup process.
The partnership unites Viz.ai's sophisticated AI algorithms, which are presently implemented in 1,700 hospitals and health systems throughout the United States and Europe, with ALCMI's patient engagement and research expertise. Viz.ai's technology enhances outcomes by providing healthcare providers with more precise and timely insights, thereby expediting diagnosis and care coordination through machine learning. Chris Mansi, MD, CEO and Co-Founder of Viz.ai, shared his enthusiasm for the partnership, stating, “We are pleased to partner with ALCMI to improve the standard of care for lung cancer patients.”
